| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human Calpain 3/CAPN3 recombinant protein (Position: I42-D764) was used as the immunogen for the CAPN3 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
CAPN3 Antibody / Calpain 3 is a anti-CAPN3 Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as Western blot (WB), ELISA with listed reactivity in Human, Mouse.
Key elements and design rationale
- Target: CAPN3
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): WB, ELISA
Biological background
Functionally, CAPN3 antibody identifies a 821-amino-acid protease characterized by catalytic cysteine and histidine residues forming the proteolytic triad. Calpain 3 associates with titin in the sarcomere and modulates proteolytic remodeling during muscle contraction and regeneration. Its activity is tightly regulated by calcium binding and autolytic activation mechanisms unique to muscle tissue.
The CAPN3 gene is located on chromosome 15q15.1 and is expressed predominantly in skeletal muscle. Calpain 3 acts as a muscle-specific regulator controlling sarcomeric integrity and signaling pathways that respond to mechanical stress and injury. It is rapidly activated upon calcium influx, enabling dynamic structural adaptation.
Pathologically, mutations in CAPN3 cause limb-girdle muscular dystrophy type 2A (LGMD2A), an autosomal recessive disorder characterized by progressive muscle weakness and atrophy. Deficiency of Calpain 3 disrupts sarcomere homeostasis and impairs muscle repair. Research using CAPN3 antibody supports studies in muscle physiology, proteolysis, and dystrophic disease mechanisms.
CAPN3 antibody is validated for western blotting, immunohistochemistry, and immunofluorescence to detect muscle-specific proteases.
Structurally, Calpain 3 consists of protease core domains (PC1 and PC2) flanked by unique insertion sequences IS1 and IS2, which confer muscle-specific regulation. This antibody aids investigation of CAPN3's enzymatic role in sarcomere remodeling and muscular dystrophy.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
